VIDEO: Survival improved among ALS patients treated with nanocrystal gold in study

SEATTLE — Patients with ALS who were treated with CNM-Au8 — a gold nanocrystal suspension — showed improvements in survival, a speaker said at the 2022 American Academy of Neurology annual meeting.

“This is a phase 2 study and needs a larger phase 3 confirmatory, international clinical trial,” Matthew Kiernan, PhD, DSc, the Bushell Chair of Neurology and professor of medicine at the University of Sydney in Australia, said.

The nanotherapeutic CNM-Au8 (Clene Nanomedicine) is currently in development for treatment of patients with ALS, MS and Parkinson’s disease.